2025年8月,据多家淀粉样变性患者组织在社交媒体向成员披露的消息,辉瑞公司计划于2025年底前在美国市场停止销售低剂量转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)治疗药物Vyndaqel。这一举措将使高剂量版本的Vyndamax成为辉瑞tafamidis药物家族中唯一留在市场上的产品,标志着辉瑞在2028年Vyndaqel专利到期前,对ATTR-CM治疗领域产品线的战略整合正式启动。ATTR...
Source Link2025年8月,据多家淀粉样变性患者组织在社交媒体向成员披露的消息,辉瑞公司计划于2025年底前在美国市场停止销售低剂量转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)治疗药物Vyndaqel。这一举措将使高剂量版本的Vyndamax成为辉瑞tafamidis药物家族中唯一留在市场上的产品,标志着辉瑞在2028年Vyndaqel专利到期前,对ATTR-CM治疗领域产品线的战略整合正式启动。ATTR...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.